pirfenidone has been researched along with Dermatoses in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Karampitsakos, T; Katsaras, M; Sotiropoulou, V; Tzouvelekis, A | 1 |
| Alexander, KA; Antin, JH; Blazar, BR; Cutler, CS; Du, J; Flynn, R; Hill, GR; Koreth, J; Lineburg, KE; Loschi, M; Luznik, L; MacDonald, KP; Maillard, I; Meng, J; Miklos, D; Panoskaltsis-Mortari, A; Paz, K; Ritz, J; Robinson, TM; Roy, S; Schacker, TW; Serody, JS; Vulic, A | 1 |
2 other study(ies) available for pirfenidone and Dermatoses
| Article | Year |
|---|---|
Improvement of psoriatic skin lesions following pirfenidone use in patients with fibrotic lung disease.
Topics: Humans; Lung Diseases; Psoriasis; Skin; Skin Diseases | 2023 |
Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production.
Topics: Allografts; Animals; B-Lymphocytes; Bronchiolitis Obliterans; Chemokine CCL2; Disease Models, Animal; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Interleukin-17; Macrophages; Mice; Mice, Mutant Strains; Pulmonary Fibrosis; Pyridones; Skin Diseases; T-Lymphocytes, Helper-Inducer; Transforming Growth Factor beta | 2017 |